Dr. Ikuo Inoue

Depatment of Endocrinology and Diabetes
Saitama Medical University, Japan


1991 M.D., Graduated School of Medicine, Saitama Medical University, Japan

1987 Ph.D., Faculty of Medicine, Saitama Medical University, Japan

Publications (Selected)

  1. Ishibashi S, Inaba T, Shimano H, Harada K, Inoue I, Mokuni H, Mori N, Gotoda T, Takaku F, Yamada N: Monocyte colony-stimulating factor enhances uptake and degradation of acetylated low density lipoprotein and cholesterol esterification in human monocyte-derived macrophages. J Biol Chem 265:14109-14117,1990
  2. Inoue I, Ishibashi S, Harada K, Shimano H, Gotoda T, Shimada M, Takahashi K, Ishii J, Yazaki Y, Yamada N: Overexpression of low density lipoprotein receptor on Chinese hamster ovary cells generates foam cells. Artheriosclerosis (Arterioscler Thromb Vasc Biol) 11:1310-1314,1991
  3. Inoue I, Inaba T, Motoyoshi K, Harada K, Shimano H, Kawamura M, Gotoda T, Oka T, Shiomi M, Watanabe Y, Yamada N: Macrophage colony stimulating factor prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 93:245-254,1992
  4. Yamada N, Inoue I, Kawamura M, Harada K, Watanabe Y, Shimano H, Gotoda T, Shimada M, Kohzaki K, Tsukada T: Apoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 89:706-711,1992
  5. Inoue I, Takahashi K, Kikuchi C, Katayama S: LDL-Apheresis reduces the susceptibility of LDL to in vitro oxidation in diabetic patients with hemodialysis treatment. Diabetes Care 19:1103-1107,1996
  6. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Ishii J, Shibazaki S, Nagai M, Kawazu S: Higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabetic Medicine 13:330-336,1996
  7. Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome ) in primary cultures of human vasculara (PPARaproliferator-activated receptor endothelial cells. Biochem Biophys Res Commum 246:370-374,1998
  8. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S: Lipophilic HMG-CoA reductase inhibitoror has an anti-inflammatory effect:reduction of , interleukin-6, cyclooxygenase-2, and p22phox bybmRNA levels for interleukin-1 in primaryaregulation of reroxisome proliferator-activated receptor endothelial cells. Life Sci 67:863-876,2000
  9. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S: The g) and PPARa (PPARaligands/activators for proliferator-activated receptor increase Cu2+,Zn2+-superoxide dismutase (CuZn-SOD) and decrease p22phox message expressions in primary endothelial cells. Metabolism 50: 3-11,2001
  10. Inoue I, Itoh F, Aoyagi A, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T , Katayama S: Fibrate and Statin synergistically increase and decrease the transactivation ofa/RXRathe transcriptional activities of PPAR B. Biochem Biophys Res Commun 290:131-139,2002kNF
  11. Inoue I, Koh HS, Mizotani K, Goto S, Tanaka K, Yagasaki F, Matsuda A, Nakajima T, Komoda T, Katayama S: A patient with severe hypertriglyceridemia associated with anemia and hypoalbuminemia. J Atheroscler Thromb 10:192-201,2003
  12. Inoue I, agonist, Ag agonist, PPARaKatayama S: The possible of actions of drugs: PPAR HMG-CoA reductase inhibitor, ACE inhibitor, or Ca-antagonist on vascular endothelial cells as therapeutic targets. Current drug target-cardiovascular & hematological disorders 4:35-52,2004
  13. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, Greenberg JH: A peroxisome agonist reduces infarct size in transient butgproliferator-activated receptor not in permanent ischemia. Stroke 36:353-359,2005
  14. Inoue I, Shinoda Y, Ikeda M, Hayashi K, Kanazawa K, Nomura M, Matsunaga T, Xu H, Kawai S, Awata T, Komoda T, Katayama S: CLOCK/BMAL1 is involved in lipid metabolism via transactivation of the peroxisome proliferator-activated receptor (PPAR) response element. J Atheroscler Thromb 12:169-174,2005
  15. Nakano T, Inoue I, Koyama I, Kanazawa K, Nakamura K, Narisawa S, Tanaka K, Akita M, Masuyama T, Seo M, Hokari S, Katayama S, Alpers DH, Millan JL, Komoda T: Disruption of the murine intestinal alkaline phosphatase gene Akp3 impairs lipid transcytosis and induces visceral fat accumulation and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 292:G1439-1449,2007
  16. Seo M, Inoue I, Ikeda M, Nakano T, Takahashi T, Katayama S, Komoda T: Statins activate human PPARa promoter and increase PPARa mRNA expression and activation in HepG2 cells. PPAR Research 2008:1-11,2008(Article ID 316306,PMID: 19125197)
  17. Nakano T, Inoue I, Seo M, Takahashi S, Awata T, Komoda T, Katayama S: Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat Cardiovasc Drug Discov 4:31-36,2009
  18. Sasa M, Inoue I, Shinoda Y, Takahashi S, Seo M, Komoda T, Awada T, Katayama S: Activating effect of momordin, an extract of bitter melon (Momordica charanfia L.), on the promoter .dof PPAR J Atheroscler Thromb 2009;16(6):888-92. Epub 2009 Dec 22.
  19. Takahashi S, Inoue I, Nakajima Y, Seo M, Nakano T, Kumagai M, Yang F, Komoda T, Awata T, Ikeda M, Katayama S: A promoter in the novel exon of hPPARγ directs the circadian expression of PPARγ. J Atheroscler ThrombFeb 17:73-83, 2010
  20. Inoue I, Awata T,Katayama S. Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: Are there disappearance thresholds for small dense LDL and IDL? Recent Pat Cardiovasc Drug Discov 5; 143-52, 2010